European Commission approves Novo Nordisk's injectable drug for obesity

By

The European Commission has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects approximately 10 to 30 percent of adults in the European Union.

The injectable drug, to be marketed as Saxenda, is already approved by health regulators in the United States.

The Danish drug maker expects to launch Saxenda in several European markets starting in 2015, it said in a statement.

Tags
European Commission, European Union
Join the Discussion
More News
diddy suing peacock

Diddy Jury Deadlocked on Racketeering; Buzbee Predicts Guilty Verdicts on Other Charges

Idaho Shooter_07012025_1

Idaho Firefighter Shooting Suspect Had Expressed Desires to Be a Fireman Himself, Grandpa Says

Bryan Kohberger

Bryan Kohberger Agrees To Plead Guilty in Murder of Idaho College Students

Sonoma County Wildfires

Sniper Found Dead in Idaho Woods After Intentionally Setting Blaze to Lure Two Firefighters to Their Deaths